Having trouble accessing articles? Reset your cache.

Medicines Co. cardiovascular news

The U.S. Patent and Trademark Office (PTO) granted a one-year interim extension for a patent covering anticoagulant Angiomax bivalirudin from The Medicines Co. The decision follows

Read the full 264 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE